Niche CRO Helix Diagnostics operates as an emerging Contract Research Organization specializing in oligonucleotide therapeutics, presenting a targeted sales opportunity to biotech clients developing RNA and DNA drugs who require specialized toxicology and safety testing.

One Stop Assay The proprietary high-throughput assay that measures Identity, Quantity, and Metabolites from a single sample offers a compelling value proposition for clients seeking to streamline analytics and reduce sample and method complexity, opening doors to partnership discussions with oligo drug developers.

Cost Savings Highlight potential client savings in assay costs and tox/safety study milestones through Helix’s consolidated workflow, positioning Helix as a cost-efficient partner for early-stage to development-stage RNA/DNA therapeutics programs.

Strategic Partnerships Recent collaboration activity with Ginkgo Bioworks on pooled COVID-19 testing and prior educational partnerships indicate receptiveness to co-development or pilot programs, suggesting opportunity for multi-entity collaborations or funded pilots with biotech ecosystems.

Growth Signals Revenue is in a viable range for a small CRO seed-stage player; target mid-market biotech firms and university-affiliated research programs seeking scalable, high-throughput toxicology support as the oligonucleotide therapeutics market expands.